Pharmaceuticals, Biotechnology and Life Sciences
Proposed merger would add a differentiated Phase 3 TROP2 Antibody-drug Conjugate (ADC) to the combined company’s pipelinePALO ALTO, Calif., Dec.…
GRANTS, NEW MEXICO, Dec. 27, 2024 (GLOBE NEWSWIRE) — Bright Green Corporation (OTC: BGXX) (“Bright Green” or the “Company”) announced…
Intend to announce updated clinical data from Phase 1/2 VBP301 trial of VCAR33ALLO in the first half of 2025 and…
LYTENAVA™ is the first and only approved ophthalmic formulation of bevacizumab for the treatment of wet AMD in the European…
STAMFORD, Conn., Dec. 27, 2024 (GLOBE NEWSWIRE) — Cara Therapeutics, Inc. (Nasdaq: CARA) (the “Company”), today announced that a 1-for-12…
VYVDURA® now approved for at-home self-injection in Japan for both generalized myasthenia gravis and CIDP argenx’s VYVGART® and VYVDURA portfolio…
Wuxi, China, Dec. 26, 2024 (GLOBE NEWSWIRE) — Park Ha Biological Technology Co., Ltd. (the “Company”), a company focused on…
SAN DIEGO, Dec. 26, 2024 (GLOBE NEWSWIRE) — Viracta Therapeutics, Inc. (Nasdaq: VIRX), a clinical-stage precision oncology company focused on…
The JPM Healthcare Conference is the largest and most informative health care investment symposium in the industry which connects global…
– ABI-4334 was well-tolerated with a favorable safety profile and half-life supporting once-daily oral dosing observed – – In the…